Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant SARS-CoV-2 vaccine (CHO cell)
- Development stage
- Phase 2
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The recombinant SARS-CoV-2 vaccine (CHO cell), specifically the candidate known as SCoK, is a protein subunit vaccine developed by the Jiangsu Provincial Center for Disease Control and Prevention in collaboration with CSPC Pharmaceutical Group. The vaccine utilizes a recombinant version of the SARS-CoV-2 spike protein's receptor-binding domain (RBD) as its primary antigen, which is expressed in Chinese Hamster Ovary (CHO) cells. By presenting the RBD to the immune system, the vaccine aims to induce the production of neutralizing antibodies that prevent the virus from binding to the host's ACE2 receptor, thereby blocking viral entry. SCoK is typically formulated with an aluminum hydroxide adjuvant to enhance immunogenicity and is administered via intramuscular injection. Clinical development reached Phase 2 trials, where it demonstrated a favorable safety profile and the ability to elicit robust immune responses in both adult and elderly populations.
- Other names
- Recombinant Novel Coronavirus Vaccine (CHO Cell)SCoK COVID-19 VaccineCSPC COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on recombinant SARS-CoV-2 vaccine (CHO cell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant SARS-CoV-2 vaccine (CHO cell).